BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine
BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine
Genentech
Private
Genentech, a member of the Roche Group, is a leading biotechnology company pioneering breakthrough medicines for serious diseases. With a 40+ year history of biotech innovation, Genentech develops therapeutics across oncology, immunology, neuroscience, ophthalmology, and infectious diseases, and is currently undergoing a strategic R&D restructuring in 2026.
Company Info
Sector:Biotechnology / Therapeutics
Headquarters:South San Francisco, California, USA
Founded:1976
Website:www.gene.com/
Funding Round:N/A (wholly-owned Roche subsidiary since 2009)
Total Funding:N/A
Funding & Investor Relations
Notable Investors
- Roche Holding AG (parent company since 2009)
IPO Outlook / Plans
N/A (Roche is the ultimate parent; fully acquired in 2009 for $46.8B)
Upcoming Milestones & Key Dates
Q2 2026
Earnings
Q1 2026 Earnings (Roche Group) — Genentech restructuring update
Q3 2026
Restructuring
Completion of infectious disease unit wind-down
Clinical Development Pipeline
Hemlibra (emicizumab)
Target: Bispecific antibody bridging Factor IXa and Factor XTecentriq (atezolizumab)
Target: Anti-PD-L1 monoclonal antibodyVabysmo (faricimab)
Target: Bispecific anti-VEGF/Ang-2 antibodyRecent News
Genentech doubles down on ADC-resistance via $1B DualityBio pact
Genentech signs a $1B collaboration with Duality Biologics to develop next-generation antibody-drug conjugates targeting resistance mechanisms in cancer.
Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio
Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio
Genentech culls 103 jobs, inks $490M-plus biobucks deal with Astex
Genentech lays off 103 employees while signing a $490M-plus biobucks collaboration with Astex Pharmaceuticals for breast cancer therapeutics. (Source: BioSpace, 2026-07-06)
Exclusive: Genentech Lays Off Top Scientist Vishva Dixit, Closes Infectious Disease Research Unit in Restructuring
An Endpoints News exclusive: Genentech is closing its infectious disease research unit and laying off longtime top scientist Vishva Dixit as part of a broader R&D restructuring that will affect hundreds of roles in South San Francisco.
Genentech R&D Layoffs Hit Top Exec Who's Been With the Biotech Nearly 30 Years
Genentech is laying off R&D staff including a top executive who had been with the Roche subsidiary for nearly 30 years, as part of a broader restructuring that is also closing some research units.
3 Genentech VPs Among Those Dismissed in Latest Layoff Round
Genentech's ongoing R&D restructuring has now reached the VP level, with three senior vice presidents among those dismissed in the latest wave, including longtime infectious disease research leader Vishva Dixit.